This inventor holds 1 USPTO granted patent. Top assignee: Korea Institute of Science and Technology. Active years: 2008.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2008
Title: Innovations of Satish N Chavre in Tetrahydrofuran Derivatives
Introduction
Satish N Chavre is a notable inventor based in Seoul, South Korea. He has made significant contributions to the field of chemistry, particularly in the development of tetrahydrofuran derivatives. His work focuses on compounds that have potential applications in drug synthesis.
Latest Patents
Chavre holds a patent for "Tetrahydrofuran derivatives having cis substituent, their intermediates, and their preparation method." This invention relates to a tetrahydrofuran compound featuring cis substituents, along with its derivatives and a method for their preparation. The patent describes a dihydrofuran-3-ylidene triflate compound that is synthesized through a Prins-type cyclization using a homopropargylic alcohol derivative as a starting material in the presence of a Lewis acid catalyst. The resulting tetrahydrofuran compounds are characterized by novel structures that are useful in synthesizing drugs, such as antagonists for neurokinin receptors. Chavre's patent portfolio includes 1 patent.
Career Highlights
Satish N Chavre is affiliated with the Korea Institute of Science and Technology, where he conducts his research and development activities. His work has been instrumental in advancing the understanding and application of tetrahydrofuran derivatives in medicinal chemistry.
Collaborations
Chavre has collaborated with notable colleagues, including Hyunah Choo and Ae Nim Pae, contributing to various research projects and innovations in the field.
Conclusion
Satish N Chavre's innovative work in tetrahydrofuran derivatives showcases his expertise and commitment to advancing chemical research. His contributions have the potential to impact drug development significantly.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
